Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to determine whether LCQ908 effectively lowers liver fat, as assessed by MRI and to assess its safety and tolerability profile in subjects with non-alcoholic fatty liver disease (NAFLD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat

NCT07214870

Fatty Liver Disease

RECRUITING PHASE1

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

NCT01514461

Familial Chylomicronemia Syndrome (FCS)

COMPLETED PHASE3

A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease

NCT01277094

Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD

COMPLETED PHASE1

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

NCT03776175

Non-Alcoholic Fatty Liver Disease (NAFLD)

COMPLETED PHASE2

Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease

NCT05768334

NAFLD

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-alcoholic Fatty Liver Disease (NAFLD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Patients randomized to Placebo arm, received matching placebo to 5 mg, 10 mg and 20 mg pradigstat (LCQ908) once daily for 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.

pradigastat (LCQ908) 5mg/10mg

Patients, randomized to pradigastat 5/10 mg, initially began with pradigastat (LCQ908) 5 mg once daily and then were up-titrated, if pradigastat (LCQ908) 5 mg once daily was tolerated, to pradigastat 10 mg once daily at Week 2. Total treatment duration was 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.

Group Type EXPERIMENTAL

LCQ908

Intervention Type DRUG

LCQ908 5 mg, 10 mg, 20 mg tablets

pradigastat (LCQ908) 10mg/20mg

Patients, randomized to pradigastat 10/20 mg, initially began with pradigastat (LCQ908) 10 mg once daily and then were up-titrated, if pradigastat (LCQ908) 10 mg once daily was tolerated, to pradigastat 20 mg once daily at Week 2. Total treatment duration was 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.

Group Type EXPERIMENTAL

LCQ908

Intervention Type DRUG

LCQ908 5 mg, 10 mg, 20 mg tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LCQ908

LCQ908 5 mg, 10 mg, 20 mg tablets

Intervention Type DRUG

placebo

Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

pradigastat

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* History of liver steatosis during the preceding 24 months
* History of fasting TGs \> 200 mg/dL (confirmed at screening).
* Liver fat ≥ 10% as determined by the central MRI laboratory.
* Subjects on the following medications can be included if these medications are medically necessary, cannot be stopped and the investigator feels their dose will remain stable for the duration of the double-blind treatment period:

1. Stable dose of anti-diabetic medications (metformin and/or sulfonylureas) for at least 8 weeks prior to screening.
2. Stable doses of beta-blockers and thiazide diuretics for at least 8 weeks prior to screening.
3. Stable doses of fibrates, statins, niacin, ezetimibe for at least 8 weeks prior to screening.
4. Stable dose of vitamin E in patients taking \>200 IU/day for at least 6 months prior to screening.

Exclusion Criteria

* Treatment with omega-3-acid ethyl esters or omega-3-polyunsaturated fatty acid (PUFA)-containing supplements \> 200 mg per day within 8 weeks of screening.
* Treatment with antiretrovirals, tamoxifen, methotrexate, cyclophosphamide, isotretinoin, bile acid binding resins or pharmacologic doses of oral glucocorticoids (≥10 mg of prednisone per day or equivalent) within 8 weeks of screening.
* ALT or AST \> 250 IU/L at the time of screening.
* History/current evidence of heavy alcohol use or alcoholism (\> 21 drinks per week in men and \> 14 drinks per week in women) over a 2-year period prior to screening.
* Presence of chronic liver disease, such as chronic hepatitis B and/or C, alcoholic liver disease, hemochromatosis, Wilson's disease, known cirrhosis.
* Platelet count \<150,000 at screening.
* BMI \>45 Kg/m2.

Minimum Eligible Age

18 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No